drugset / Trial / NCT06244368
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Phase 2
Recruiting
115 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Affiliated Cancer Hospital & Institute of Guangzhou Medical University · collabBeijing Tongren Hospital · collabChengdu Shangjin Nanfu Hospital · collabChina-Japan Friendship Hospital · collabFirst Affiliated Hospital of Harbin Medical University · collabFirst Hospital of China Medical University · collabHebei Medical University Fourth Hospital · collabPeking University Third Hospital · collabPeople's Hospital of Zhengzhou University · collabShengjing Hospital · collabThe Affiliated Ganzhou Hospital of Nanchang University · collabThe First Affiliated Hospital of Bengbu Medical University · collabThe First Affiliated Hospital of Dalian Medical University · collabThe First Affiliated Hospital of Nanchang University · collabThe First Hospital of Jilin University · collabThe Second Affiliated Hospital of Harbin Medical University · collabThe Second Affiliated Hospital of Kunming Medical University · collabXuanwu Hospital, Beijing · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
Timeline
- Start
- 2024-01-17
- Primary completion
- 2025-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitoxantrone | Small molecule | 18 mg/m2 | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Gemcitabine | Small molecule | 800 mg/m2 | — |
| Background | Vinorelbine | Small molecule | 20 mg/m2 | — |